Novocardia Life Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.04 Cr
as on 20-12-2024
- Revenue 107.96%
(FY 2023)
- Profit 1831.58%
(FY 2023)
- Ebitda 571.69%
(FY 2023)
- Net Worth 413.92%
(FY 2023)
- Total Assets 63.23%
(FY 2023)
About Novocardia Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.04 Cr.
Aaditya Kumar, Sweta Nathani, and Anshu Agrawal serve as directors at the Company.
- CIN/LLPIN
U24110WB2019PTC233252
- Company No.
233252
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Novocardia Life Science?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sweta Nathani | Managing Director | 25-Feb-2023 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aaditya Kumar  | Whole-Time Director | 02-Aug-2019 | Current |
| Anshu Agrawal | Director | 02-Aug-2019 | Current |
Financial Performance of Novocardia Life Science.
Novocardia Life Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 107.96% increase. The company also saw a substantial improvement in profitability, with a 1831.58% increase in profit. The company's net worth Soared by an impressive increase of 413.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novocardia Life Science?
Unlock access to Novocardia Life Science's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Dec 2023 | ₹3.50 M | Open |
Hdfc Bank Limited Creation Date: 27 Oct 2021 | ₹4.90 M | Open |
Hdfc Bank Limited Creation Date: 10 Feb 2021 | ₹2.00 M | Open |
How Many Employees Work at Novocardia Life Science?
Unlock and access historical data on people associated with Novocardia Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novocardia Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novocardia Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
